Biological AgingNCT07322224
Multi-Modal Longevity Protocol Including Autologous Cell-Free Conditioned Media
A study testing Multi-Modal Longevity Protocol in people with Biological Aging and Healthy Aging, run by BlueBird Age Reversal SA at 1 site in United Kingdom.
Trial summary
This pilot study evaluated a multi-modal longevity protocol combining lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media derived from peripheral blood-derived pro-regenerative cells (APRC-CM). Read more about this study
- Who is it for?
- Ages 45 years and olderHealthy volunteers can take part
- Conditions the study is for
- Biological Aging, Healthy Aging, Longevity
- What is being tested?
- Multi-Modal Longevity Protocol
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 5 Aug 2024to 20 Mar 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 45 years or older
- Generally good overall health as assessed by the study team
- Able and willing to provide written informed consent
- Willing to participate in all components of the study protocol, including lifestyle optimisation, nutritional supplementation, blood collection, and scheduled follow-up visits
- Able to comply with study procedures for the duration of the intervention and assessments
Who cannot join
- Presence of a major medical condition that, in the opinion of the investigators, could affect participation or safety
- Any condition requiring hospitalization or emergency medical intervention within the past 12 months
- Receipt of anti-aging or longevity treatments within the past six months (e.g., intravenous therapies, regenerative or cellular treatments, structured age-reversal programmes)
- Active infectious disease at enrolment
- Pregnancy or breastfeeding
- Use of systemic immunomodulatory, cytotoxic, or investigational treatments in the prior 3 months
- Any condition or circumstance that, in the judgement of the investigators, may interfere with study participation or data integrity
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Wellbeing International Foundation
London, W1G 0PG
About this study
Official title: A Multi-Modal Longevity Protocol Integrating Lifestyle, Supplements, and Autologous Pro-Regenerative Cell-Conditioned Media: A Pilot Study
This pilot study evaluated a multi-modal longevity protocol combining lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media derived from peripheral blood-derived pro-regenerative cells (APRC-CM). Fourteen healthy adult participants completed a 17-week programme including baseline and post-intervention biomarker assessments. The primary objective was to characterise changes in biological age using DNA methylation-based epigenetic clocks, PhenoAge and other physiological and biochemical markers.
Read the detailed description
This exploratory study investigated the biological effects of a structured, multi-modal longevity programme that included lifestyle optimisation (nutrition, exercise, sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells cultured ex vivo to produce a pro-regenerative secretome containing soluble factors and extracellular vesicles.
Participants underwent biomarker assessments at baseline and at week 17. Outcomes included measurements of epigenetic biological age, phenotypic age, inflammatory markers, metabolic markers, and other laboratory and physiological variables. The study was conducted in healthy adults and designed as a minimal-risk physiological investigation.
- Conditions
- Biological Aging, Healthy Aging, Longevity
- Being tested
- Multi-Modal Longevity Protocol
- Keywords
- Epigenetic age, Phenotypic age, Autologous conditioned media, Longevity protocol, Supplements, Lifestyle
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multi-Modal Longevity ProtocolBehavioural
The intervention consisted of a structured, multi-modal longevity program that included lifestyle optimization (nutrition, physical activity, and sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells and administered as part of a physiologic, minimal-risk exploratory protocol.
| Study group | Role | What they receive |
|---|---|---|
| Longevity Protocol Arm | Experimental | Participants received a structured, multi-modal longevity protocol consisting of lifestyle optimization, nutritional supplementation, and autologous cell-free conditioned media (APRC-CM) prepared individually from peripheral blood-derived pro-regenerative cells. All participants received the same intervention schedule over a 17-week period. Receives: Behavioral: Multi-Modal Longevity Protocol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Epigenetic Biological Age
Biological age calculated from DNA methylation profiles using validated epigenetic clock algorithms.
Measured: Baseline and Week 17
Secondary outcomes (1)
Change in Phenotypic Age
Phenotypic age calculated from clinical biomarkers using published phenotypic age algorithms.
Measured: Baseline and Week 17
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2026
- Study start5 Aug 2024
- Primary completion15 Dec 2024
- Study completion20 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Biological AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single-arm exploratory study in which all participants received the same multi-modal longevity protocol, including lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). No comparator group was included.
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- BlueBird Age Reversal SA
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- xLongevity, Wellbeing International Foundation
- Responsible party
- Sponsor
- Investigators
- Esteban Ortega, MD, Principal investigator, Wellbeing International Foundation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07322224
- Sponsor's protocol ID
- BB-ART3-2024-PILOT
- Status last verified
- Dec 2025
- First submitted
- 5 Dec 2025
- Last updated
- 7 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because the dataset includes biological, clinical, and demographic information that may be potentially identifiable, and no data-sharing agreements or infrastructure were established for this pilot study.
Publications
Ortega E, Addor G, Bhatia S, Lewinsohn M, Sottas PE. A multi-modal longevity protocol integrating lifestyle, supplements, and autologous pro-regenerative cell-conditioned media: a pilot study. Front Aging. 2026 Jun 25;7:1732426. doi: 10.3389/fragi.2026.1732426. eCollection 2026.
PubMed 42428158
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-Modal Longevity Protocol Integrating Lifestyle, Supplements, and Autologous Pro-Regenerative Cell-Conditioned Media: A Pilot Study
- ClinicalTrials.gov ID
- NCT07322224
- Acronym / sponsor ID
- BB-ART3-2024-PILOT
- Conditions
- Biological Aging, Healthy Aging, Longevity
- Keywords
- Epigenetic age, Phenotypic age, Autologous conditioned media, Longevity protocol, Supplements, Lifestyle
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- BlueBird Age Reversal SAIndustry (pharma, biotech, devices)
- Collaborators
- xLongevity, Wellbeing International Foundation
- Study start
- 5 Aug 2024 (actual)
- Primary completion
- 15 Dec 2024 (actual)
- Study completion
- 20 Mar 2025 (actual)
- First posted
- 7 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This pilot study evaluated a multi-modal longevity protocol combining lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media derived from peripheral blood-derived pro-regenerative cells (APRC-CM). Fourteen healthy adult participants completed a 17-week programme including baseline and post-intervention biomarker assessments. The primary objective was to characterise changes in biological age using DNA methylation-based epigenetic clocks, PhenoAge and other physiological and biochemical markers.
Detailed description
This exploratory study investigated the biological effects of a structured, multi-modal longevity programme that included lifestyle optimisation (nutrition, exercise, sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells cultured ex vivo to produce a pro-regenerative secretome containing soluble factors and extracellular vesicles.
Participants underwent biomarker assessments at baseline and at week 17. Outcomes included measurements of epigenetic biological age, phenotypic age, inflammatory markers, metabolic markers, and other laboratory and physiological variables. The study was conducted in healthy adults and designed as a minimal-risk physiological investigation.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single-arm exploratory study in which all participants received the same multi-modal longevity protocol, including lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). No comparator group was included.
| Arm | Type | Receives |
|---|---|---|
| Longevity Protocol Arm | Experimental | Behavioral: Multi-Modal Longevity ProtocolParticipants received a structured, multi-modal longevity protocol consisting of lifestyle optimization, nutritional supplementation, and autologous cell-free conditioned media (APRC-CM) prepared individually from peripheral blood-derived pro-regenerative cells. All participants received the same intervention schedule over a 17-week period. |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age 45 years or older
- Generally good overall health as assessed by the study team
- Able and willing to provide written informed consent
- Willing to participate in all components of the study protocol, including lifestyle optimisation, nutritional supplementation, blood collection, and scheduled follow-up visits
- Able to comply with study procedures for the duration of the intervention and assessments
Key exclusion criteria (7 listed)
- Presence of a major medical condition that, in the opinion of the investigators, could affect participation or safety
- Any condition requiring hospitalization or emergency medical intervention within the past 12 months
- Receipt of anti-aging or longevity treatments within the past six months (e.g., intravenous therapies, regenerative or cellular treatments, structured age-reversal programmes)
- Active infectious disease at enrolment
- Pregnancy or breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multi-Modal Longevity ProtocolThe intervention consisted of a structured, multi-modal longevity program that included lifestyle optimization (nutrition, physical activity, and sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells and administered as part of a physiologic, minimal-risk exploratory protocol. | Behavioural | Longevity Protocol Arm |
Primary outcome
Change in Epigenetic Biological Age
Time frame: Baseline and Week 17
Biological age calculated from DNA methylation profiles using validated epigenetic clock algorithms.
1 secondary outcome
Change in Phenotypic Age
Time frame: Baseline and Week 17
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2026.
- Derived from this study: PubMed 42428158Ortega E, Addor G, Bhatia S, Lewinsohn M, Sottas PE. A multi-modal longevity protocol integrating lifestyle, supplements, and autologous pro-regenerative cell-conditioned media: a pilot study. Front Aging. 2026 Jun 25;7:1732426. doi: 10.3389/fragi.2026.1732426. eCollection 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because the dataset includes biological, clinical, and demographic information that may be potentially identifiable, and no data-sharing agreements or infrastructure were established for this pilot study.
Related trials for Biological Aging
Not yet recruitingObservational study
Biological Aging Following Full-Arch Implant-Supported Fixed Rehabilitation in Edentulous Patients
Edentulism, Biological Aging
Enrolling by invitationEarly Phase 1
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
Aging
Active, not recruiting
Effects of a Multi-Targeted Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido and Epigenetic Biological Clock Age
Skin Ageing, Healthy Ageing
RecruitingPhase 4
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
Obesity, Menopause Hot Flashes
Recruiting
The Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults
Aging, Mobility Disability
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Esteban Ortega, MD principal investigator
Wellbeing International Foundation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multi-Modal Longevity Protocol in people with Biological Aging and Healthy Aging, run by BlueBird Age Reversal SA at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Epigenetic Biological Age (time frame: Baseline and Week 17). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07322224, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.